GLSI

Rating neutralAI Memo

Greenwich LifeSciences

As of 2026-08-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Additional FLAMINGO-01 open-label data • 2026-09-17

Base target: $13 / p=55% prob

Biggest risk

The company has no revenue, reported a $5.7 million first-quarter net loss, used $4.7 million in operating cash, and stated that substantial doubt exists about continuing as a going concern without additional capital. Financing needs, dilution, trial timing, and clinical uncertainty dominate the downside case [#SEC-10Q-2026-06-04].

Invalidation

Break below $9 or thesis failure.

What would change my mind?

GLSI offers asymmetric clinical upside if FLAMINGO-01 data continue to support GLSI-100 and the company advances enrollment, manufacturing, and regulatory readiness. The Phase III program and preliminary open-label data provide genuine event-driven upside, but the evidence remains preliminary [#SEC-10Q-2026-06-04] [#PR-2026-03-17].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-04

Base target

$13

p=55%

Bull target

$20

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Liquidity cushion from ATM financing
Follow-on financing and dilution risk
Phase III event accrual and manufacturing readiness

BearKey bullets

Dependence on third-party manufacturers for clinical-trial materials creates execution and supply risk [#SEC-10Q-2026-06-04].
FLAMINGO-01 efficacy, event accrual, interim timing, and regulatory outcomes remain uncertain.
Ongoing ATM financing may extend runway but increases dilution risk [#SEC-10Q-2026-06-04].

WatchKey bullets

Additional FLAMINGO-01 open-label data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $13 (p=55%)

Target spread vs base: +54% / -31%

Scenario probabilities

Bull Target: $20 (p=20%)Base Target: $13 (p=55%)Bear Target: $9 (p=25%)

Commentary

The single recent secondary headline was constructive, but coverage is sparse and no social, options, short-interest, or analyst-revision evidence is available in the packet. Deterministic evidence is negative despite strong filing coverage; this remains a low-coverage, event-driven monitoring setup rather than a high-conviction long.

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Liquidity cushion from ATM financing
Follow-on financing and dilution risk
Phase III event accrual and manufacturing readiness

Scenarios

Bull Target (Scenario probability)

$20 / p=20% prob

Base Target (Scenario probability)

$13 / p=55% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-17
Additional FLAMINGO-01 open-label data
A March 2026 company update described preliminary recurrence data from the fully enrolled open-label arm and indicated that further data could be presented at future conferences. The dataset remains preliminary and company-reported [#PR-2026-03-17].
Prob 50.00% • Move 20.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Liquidity cushion from ATM financing
2026-11-02
The company reported $10.5 million of cash at March 31, 2026, raised $9.0 million net through its ATM in the first quarter, and raised an additional $0.31 million net through April 15. This improves near-term liquidity but remains offset by ongoing operating cash burn and dependence on additional capital [#SEC-10Q-2026-06-04].
Prob 80% • Move 8% • Priced-in 65%
Follow-on financing and dilution risk
2026-11-02
The company has no revenue, used $4.7 million of cash in operations during the first quarter, and disclosed substantial doubt about continuing as a going concern without additional capital [#SEC-10Q-2026-06-04].
Prob 65% • Move -20% • Priced-in 45%

Long-term Catalysts

Months to a year

Phase III event accrual and manufacturing readiness
2027-06-30
FLAMINGO-01 is an ongoing Phase III study of GLSI-100, with planned expansion into Europe and up to 150 global sites. Prior company updates cited screening progress, commercial-lot use, and the study's event-driven interim design; sustained accrual and manufacturing execution would be the clearest path to de-risking [#SEC-10Q-2026-06-04] [#PR-2026-01-22] [#PR-2026-03-03].
Prob 35% • Move 45% • Priced-in 20%

Risks

Dependence on third-party manufacturers for clinical-trial materials creates execution and supply risk [#SEC-10Q-2026-06-04].
FLAMINGO-01 efficacy, event accrual, interim timing, and regulatory outcomes remain uncertain.
Ongoing ATM financing may extend runway but increases dilution risk [#SEC-10Q-2026-06-04].
Substantial doubt about continuing as a going concern and dependence on additional capital [#SEC-10Q-2026-06-04].
The company has no revenue and continues to incur significant research and development expenses [#SEC-10Q-2026-06-04].

Peers

Symbol	Summary
ANTX	Same-sector, similar-market-cap comparator from the packet; useful for small-cap biotech event volatility, but not established as a close stage- or mechanism-matched peer.
GALT	Same-sector, similar-market-cap comparator; valuation comparison is loose because the packet does not provide detailed operating or pipeline comparability.
KROS	Same-sector, similar-market-cap comparator; relevant mainly as a broad biotech reference rather than a direct clinical or commercial comp.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

ANTX

Same-sector, similar-market-cap comparator from the packet; useful for small-cap biotech event volatility, but not established as a close stage- or mechanism-matched peer.

GALT

Same-sector, similar-market-cap comparator; valuation comparison is loose because the packet does not provide detailed operating or pipeline comparability.

KROS

Same-sector, similar-market-cap comparator; relevant mainly as a broad biotech reference rather than a direct clinical or commercial comp.